Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Crescent cancer trial takes CR-001 to ASCO 2026, first data expected in 2027

Summary by stocktitan.net
First CR-001 clinical data are planned from Q1 2027, after ASCEND enrolls up to 290 patients with solid tumors in Crescent's global Phase 1/2 trial.

2 Articles

The Manila TimesThe Manila Times
Lean Right

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients

·Manila, Philippines (the)
Read Full Article
stocktitan.netstocktitan.net

Crescent cancer trial takes CR-001 to ASCO 2026, first data expected in 2027

First CR-001 clinical data are planned from Q1 2027, after ASCEND enrolls up to 290 patients with solid tumors in Crescent's global Phase 1/2 trial.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news on Thursday, May 21, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Crescent icon

Crescent

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal